Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers

Clinical Colorectal Cancer

Volumn 4, Issue 1, 2004, Pages 46-50

  Jordan, Karin ^a   Kellner, Olaf ^a   Kegel, Thomas ^a   Schmoll, Hans Joachim ^a   Grothey, Axel ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

Combination therapy; Diarrhea; Gastric cancer; Hand foot syndrome; Pancreatic cancer

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE DERIVATIVE; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM CANCER; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALE; NEUROTOXICITY; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SALVAGE THERAPY; STATISTICAL SIGNIFICANCE; STOMACH CANCER; THROMBOCYTOPENIA;

EID: 3042562289     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.n.009     Document Type: Article

References (24)

1. Ragnhammar P, Hafstrom L, Nygren P, et al. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40:282-308.
2. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321:531-535.
3. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21:129a (Abstract #512).
4. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
5. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
8. Meta-analysis group in cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.
9. Koehne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003; 21:3721-3728.
10. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097-4106.
11. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19:2282-2292.
12. Tewes M, Schleucher N, Achterrath W, et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study dagger. Ann Oncol 2003; 14:1442-1448.
13. Diaz-Rubio E, Evans TR, Tabemero J, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002; 13:558-565.
14. Grothey A, Jordan K, Kellner O, et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2003; 22:255 (Abstract #1022).
15. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20:1759-1766.
16. Delord J, Pierga J, Dieras V, et al. Dose escalation and pharmacokinetic study of capecitabine (Xeloda) and irinotecan (CPT-11) in gastro-intestinal tumors: preliminary results. Proc Am Soc Clin Oncol 2002; 21:100a (Abstract #397).
17. DeSantis S, Zeuli M, Di Costanzo F, et al. Oxaliplatin and capecitabine in advanced colorectal cancer: a dose-finding trial. Proc Am Soc Clin Oncol 2001; 20:141a (Abstract #559).
18. Patt YZ, Lin E, Leibmann J, et al. Capecitabine plus irinotecan for chemotherapy-naïve patients with metastatic colorectal cancer (MCRC): US multicenter phase II trial. Proc Am Soc Clin Oncol 2003; 22:281 (Abstract #1130).
19. Sastre J, Butts C, Cassidy J, et al. Capecitabine-oxaliplatin combination (XELOX), effective 1st line therapy for patients (pts) with metastatic colorectal cancer (MCRC): Survival update of an international phase II trial. Ann Oncol 2002; 13(suppl 5):80 (Abstract #288P).
20. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21:1307-1312.
21. Scheithauer W, Kornek GV, Raderer M, et al. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. Ann Oncol 2002; 13:1583-1589.
22. Shields A, Zalupski M, Marshall J, et al. A phase II trial of oxaliplatin and capecitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2002; 21:143a (Abstract #568).
23. Zeuli M, Costanzo ED, Sdrobolini A, et al. Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. Ann Oncol 2001; 12:1737-1741.
24. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13:566-575.